The antiapoptotic protein, FLIP, is regulated by heterogeneous nuclear ribonucleoprotein K and correlates with poor overall survival of nasopharyngeal carcinoma patients

Cell Death and Differentiation

Volumn 17, Issue 9, 2010, Pages 1463-1473

  Chen, L C ^a   Chung, I C ^b   Hsueh, C ^a,c   Tsang, N M ^c   Chi, L M ^a   Liang, Y ^a   Chen, C C ^a   Wang, L J ^a   Chang, Y S ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

FLIP; hnRNP K; nasopharyngeal carcinoma; nucleolin; prognosis

Indexed keywords

FLICE INHIBITORY PROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; NUCLEOLIN; POLYCYTIDYLIC ACID;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FLIP GENE; GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTION REGULATION;

ADULT; AGED; APOPTOSIS; BINDING SITES; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHOPROTEINS; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RIBONUCLEOPROTEINS; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION FACTOR AP-2; UP-REGULATION;

EID: 77955711835     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2010.24     Document Type: Article

References (42)

1. Choi HS, Hwang CK, Song KY, Law PY, Wei LN, Loh HH. Poly(C)-binding proteins as transcriptional regulators of gene expression. Biochem Biophys Res Commun 2009; 380: 431-436.
2. Lee PT, Liao PC, Chang WC, Tseng JT. Epidermal growth factor increases the interaction between nucleolin and heterogeneous nuclear ribonucleoprotein K/poly(C) binding protein 1 complex to regulate the gastrin mRNA turnover. Mol Biol Cell 2007; 18: 5004-5013.
3. Barboro P, Repaci E, Rubagotti A, Salvi S, Boccardo S, Spina B et al. Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. Br J Cancer 2009; 100: 1608-1616.
4. Matta A, Tripathi SC, DeSouza LV, Grigull J, Kaur J, Chauhan SS et al. Heterogeneous ribonucleoprotein K is a marker of oral leukoplakia and correlates with poor prognosis of squamous cell carcinoma. Int J Cancer 2009; 125: 1398-1406.
5. Chen LC, Hsueh C, Tsang NM, Liang Y, Chang KP, Hao SP et al. Heterogeneous ribo-nucleoprotein k and thymidine phosphorylase are independent prognostic and therapeutic markers for nasopharyngeal carcinoma. Clin Cancer Res 2008; 14: 3807-3813.
6. Carpenter B, McKay M, Dundas SR, Lawrie LC, Telfer C, Murray GI. Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br J Cancer 2006; 95: 921-927.
7. Habelhah H, Shah K, Huang L, Ostareck-Lederer A, Burlingame AL, Shokat KM et al. ERK phosphorylation drives cytoplasmic accumulation of hnRNP-K and inhibition of mRNA translation. Nat Cell Biol 2001; 3: 325-330.
8. Notari M, Neviani P, Santhanam R, Blaser BW, Chang JS, Galietta A et al. A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood 2006; 107: 2507-2516.
9. Chen LC, Liu HP, Li HP, Hsueh C, Yu JS, Liang CL et al. Thymidine phosphorylase mRNA stability and protein levels are increased through ERK-mediated cytoplasmic accumulation of hnRNP K in nasopharyngeal carcinoma cells. Oncogene 2009; 28: 1904-1915.
10. Lynch M, Chen L, Ravitz MJ, Mehtani S, Korenblat K, Pazin MJ et al. hnRNP K binds a core polypyrimidine element in the eukaryotic translation initiation factor 4E (eIF4E) promoter, and its regulation of eIF4E contributes to neoplastic transformation. Mol Cell Biol 2005; 25: 6436-6453.
11. Inoue A, Sawata SY, Taira K, Wadhwa R. Loss-of-function screening by randomized intracellular antibodies: identification of hnRNP-K as a potential target for metastasis. Proc Natl Acad Sci USA 2007; 104: 8983-8988.
12. Michelotti EF, Michelotti GA, Aronsohn AI, Levens D. Heterogeneous nuclear ribonucleoprotein K is a transcription factor. Mol Cell Biol 1996; 16: 2350-2360.
13. Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 2008; 27: 6207-6215.
14. Yang JK. FLIP as an anti-cancer therapeutic target. Yonsei Med J 2008; 49: 19-27.
15. Ullenhag GJ, Mukherjee A, Watson NF, Al-Attar AH, Scholefield JH, Durrant LG. Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin Cancer Res 2007; 13: 5070-5075.
16. Korkolopoulou P, Goudopoulou A, Voutsinas G, Thomas-Tsagli E, Kapralos P, Patsouris E et al. c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations. Urology 2004; 63: 1198-1204.
17. Lee AW, Poon YF, Foo W, Law SC, Cheung FK, Chan DK et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 1992; 23: 261-270.
18. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998; 396: 699-703.
19. Komatsu K, Miyashita T, Hang H, Hopkins KM, Zheng W, Cuddeback S et al. Human homologue of S. pombe Rad9 interacts with BCL-2/BCL-xL and promotes apoptosis. Nat Cell Biol 2000; 2: 1-6.
20. Namen AE, Lupton S, Hjerrild K, Wignall J, Mochizuki DY, Schmierer A et al. Stimulation of B-cell progenitors by cloned murine interleukin-7. Nature 1988; 333: 571-573.
21. Schall TJ, Bacon K, Toy KJ, Goeddel DV. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990; 347: 669-671.
22. Stringa E, Knauper V, Murphy G, Gavrilovic J. Collagen degradation and platelet-derived growth factor stimulate the migration of vascular smooth muscle cells. J Cell Sci 2000; 113 (Part 11): 2055-2064.
23. Huang X, Wu J, Spong S, Sheppard D. The integrin alphavbeta6 is critical for keratinocyte migration on both its known ligand, fibronectin, and on vitronectin. J Cell Sci 1998; 111 (Part 15): 2189-2195.
24. McLeod SJ, Li AH, Lee RL, Burgess AE, Gold MR. The Rap GTPases regulate B cell migration toward the chemokine stromal cell-derived factor-1 (CXCL12): potential role for Rap2 in promoting B cell migration. J Immunol 2002; 169: 1365-1371.
25. Wei CC, Zhang SL, Chen YW, Guo DF, Ingelfinger JR, Bomsztyk K et al. Heterogeneous nuclear ribonucleoprotein K modulates angiotensinogen gene expression in kidney cells. J Biol Chem 2006; 281: 25344-25355.
26. Shnyreva M, Schullery DS, Suzuki H, Higaki Y, Bomsztyk K. Interaction of two multifunctional proteins. Heterogeneous nuclear ribonucleoprotein K and Y-box-binding protein. J Biol Chem 2000; 275: 15498-15503.
27. Eiring AM, Neviani P, Santhanam R, Oaks JJ, Chang JS, Notari M et al. Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. Blood 2008; 111: 816-828.
28. Donnem T, Al-Shibli K, Al-Saad S, Busund LT, Bremnes RM. Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival. J Thorac Oncol 2009; 4: 578-585.
29. Lai JP, Sandhu DS, Yu C, Han T, Moser CD, Jackson KK et al. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 2008; 47: 1211-1222.
30. Gu ZD, Li JY, Li M, Gu J, Shi XT, Ke Y et al. Matrix metalloproteinases expression correlates with survival in patients with esophageal squamous cell carcinoma. Am J Gastroenterol 2005; 100: 1835-1843.
31. Zhang HG, Wang J, Yang X, Hsu HC, Mountz JD. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 2004; 23: 2009-2015.
32. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J. NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol 2001; 21: 5299-5305.
33. Ricci MS, Jin Z, Dews M, Yu D, Thomas-Tikhonenko A, Dicker DT et al. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol 2004; 24: 8541-8555.
34. Zaichuk TA, Shroff EH, Emmanuel R, Filleur S, Nelius T, Volpert OV. Nuclear factor of activated T cells balances angiogenesis activation and inhibition. J Exp Med 2004; 199: 1513-1522.
35. Gao S, Lee P, Wang H, Gerald W, Adler M, Zhang L et al. The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells. Mol Endocrinol 2005; 19: 1792-1802.
36. Zhang X, Zhang L, Yang H, Huang X, Otu H, Libermann TA et al. c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res 2007; 67: 9425-9434.
37. Yang D, Wang S, Brooks C, Dong Z, Schoenlein PV, Kumar V et al. IFN regulatory factor 8 sensitizes soft tissue sarcoma cells to death receptor-initiated apoptosis via repression of FLICE-like protein expression. Cancer Res 2009; 69: 1080-1088.
38. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301-310.
39. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225-260.
40. Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 2009; 86: 151-164.
41. Gonzalez V, Guo K, Hurley L, Sun D. Identification and characterization of nucleolin as a c-myc G-quadruplex-binding protein. J Biol Chem 2009; 284: 23622-23635.
42. Tomonaga T, Levens D. Heterogeneous nuclear ribonucleoprotein K is a DNA-binding transactivator. J Biol Chem 1995; 270: 4875-4881.